Shanghai Haohai Biology Science & Technology Co., Ltd (HKG: 6826, SHA: 688366) has announced that it has received Medical Device Registration Approval from the National Medical Products Administration for its innovative amino acid cross-linked sodium hyaluronate gel. The product is indicated for injection into the middle to deep layers of dermal and subcutaneous tissue to correct moderate to severe nasolabial folds.
This breakthrough product utilizes Haohai Bio’s proprietary first-in-class organic cross-linking technology and is the only hyaluronic acid product in China that employs natural lysine, an essential amino acid, as a crosslinking agent. This natural approach offers superior long-term safety compared to traditional chemical crosslinking agents. Additionally, it is the first product in China designed to block the action site of hyaluronidase, which enhances its longevity and effectiveness.
Post-implantation, the product not only increases the volume of skin and soft tissues but also stimulates local collagen growth. It is effective in repairing facial depressions and deformities, reducing or eliminating static skin wrinkles, and adjusting facial contours. This cutting-edge product offers minimally invasive cosmetic surgery and beautification effects, setting a new standard in the aesthetic medicine space.- Flcube.com
